Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism

Journal of Neuroimmunology

Volumn 233, Issue 1-2, 2011, Pages 97-105

  Rossi, Barbara ^a   Zenaro, Elena ^a   Angiari, Stefano ^a   Ottoboni, Linda ^a   Bach, Simona ^a   Piccio, Laura ^a,b   Pietronigro, Enrica C ^a   Scarpini, Elio ^b   Fusco, Mariella ^c   Leon, Alberta ^c   Constantin, Gabriela ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE   (Italy)

Author keywords

Cannabinoid CB1 receptor; Integrins; Lymphocyte trafficking; Neuroinflammation; Protein kinase A

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CELL ADHESION MOLECULE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PADGEM PROTEIN; RIMONABANT; THEOPHYLLINE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ADHESION; CELL CYCLE ARREST; CONTROLLED STUDY; ENCEPHALITIS; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; INVERSE AGONISM; LEUKOCYTE ROLLING; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VENULE;

ANIMALS; BRAIN; CELL ADHESION; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; FEMALE; MICE; RECEPTOR, CANNABINOID, CB1; T-LYMPHOCYTE SUBSETS; VENULES;

EID: 79953307429     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.12.005     Document Type: Article

References (67)

1. Arevalo-Martin A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 2003, 23:2511-2516.
2. Battistini L., Piccio L., Rossi B., Bach S., Galgani S., Gasperini C., Ottoboni L., Ciabini D., Caramia M.D., Bernardi G., Laudanna C., Scarpini E., McEver R.P., Butcher E.C., Borsellino G., Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003, 101:4775-4782.
3. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 1996, 184:1101-1109.
4. Bolomini-Vittori M., Montresor A., Giagulli C., Staunton D., Rossi B., Martinello M., Constantin G., Laudanna C. Regulation of conformer-specific activation of the integrin LFA-1 by a chemokine-triggered Rho signaling module. Nat. Immunol. 2009, 10:185-194.
5. Bonhaus D.W., Chang L.K., Kwan J., Martin G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 1998, 287:884-888.
6. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 1995, 312(Pt 2):637-641.
7. Buckley N.E., Hansson S., Harta G., Mezey E. Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 1998, 82:1131-1149.
8. Caraceni P., Pertosa A.M., Giannone F., Domenicali M., Grattagliano I., Principe A., Mastroleo C., Perrelli M.G., Cutrin J., Trevisani F., Croci T., Bernardi M. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 2009, 58:1135-1143.
9. Carrithers M.D., Visintin I., Kang S.J., Janeway C.A. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000, 123(Pt 6):1092-1101.
10. Croci T., Landi M., Galzin A.M., Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br. J. Pharmacol. 2003, 140:115-122.
11. Daaka Y., Klein T.W., Friedman H. Expression of cannabinoid receptor mRNA in murine and human leukocytes. Adv. Exp. Med. Biol. 1995, 373:91-96.
12. Daaka Y., Zhu W., Friedman H., Klein T.W. Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor. DNA Cell Biol. 1997, 16:301-309.
13. Dyke H.J., Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs 2002, 11:1-13.
14. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
15. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol. 1992, 42:838-845.
16. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232:54-61.
17. Gonzalez S., Manzanares J., Berrendero F., Wenger T., Corchero J., Bisogno T., Romero J., Fuentes J.A., Di Marzo V., Ramos J.A., Fernandez-Ruiz J. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology 1999, 70:137-145.
18. Gross A., Terraza A., Marchant J., Bouaboula M., Ouahrani-Bettache S., Liautard J.P., Casellas P., Dornand J. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis. J. Leukoc. Biol. 2000, 67:335-344.
19. Ho B.Y., Current L., Drewett J.G. Role of intracellular loops of cannabinoid CB(1) receptor in functional interaction with G(alpha16). FEBS Lett. 2002, 522:130-134.
20. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
21. Howlett A.C., Scott D.K., Wilken G.H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem. Pharmacol. 1989, 38:3297-3304.
22. Jackson S.J., Pryce G., Diemel L.T., Cuzner M.L., Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 2005, 134:261-268.
23. Jeon Y.J., Yang K.H., Pulaski J.T., Kaminski N.E. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol. Pharmacol. 1996, 50:334-341.
24. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 1992, 42:736-742.
25. Kerfoot S.M., Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169:1000-1006.
26. Kerfoot S.M., Norman M.U., Lapointe B.M., Bonder C.S., Zbytnuik L., Kubes P. Reevaluation of P-selectin and alpha 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 176:6225-6234.
27. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5:400-411.
28. Klein T.W., Kawakami Y., Newton C., Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J. Toxicol. Environ. Health 1991, 32:465-477.
29. Klein T.W., Lane B., Newton C.A., Friedman H. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 2000, 225:1-8.
30. Klein T.W., Newton C., Larsen K., Chou J., Perkins I., Lu L., Nong L., Friedman H. Cannabinoid receptors and T helper cells. J. Neuroimmunol. 2004, 147:91-94.
31. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., Friedman H. The cannabinoid system and immune modulation. J. Leukoc. Biol. 2003, 74:486-496.
32. Klein T.W., Newton C.A., Friedman H. Cannabinoids and the immune system. Pain Res Manag 2001, 6:95-101.
33. Klein T.W., Newton C.A., Widen R., Friedman H. The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J. Immunopharmacol. 1985, 7:451-466.
34. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 1997, 334:R1-2.
35. Laudanna C., Campbell J.J., Butcher E.C. Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J. Biol. Chem. 1997, 272:24141-24144.
36. Laudanna C., Constantin G., Baron P., Scarpini E., Scarlato G., Cabrini G., Dechecchi C., Rossi F., Cassatella M.A., Berton G. Sulfatides trigger increase of cytosolic free calcium and enhanced expression of tumor necrosis factor-alpha and interleukin-8 mRNA in human neutrophils. Evidence for a role of L-selectin as a signaling molecule. J. Biol. Chem. 1994, 269:4021-4026.
37. Lee M., Yang K.H., Kaminski N.E. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. Ther. 1995, 275:529-536.
38. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
39. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl Acad. Sci. USA 1992, 89:3825-3829.
40. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 2000, 97:9561-9566.
41. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
42. McCoy K.L., Gainey D., Cabral G.A. delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J. Pharmacol. Exp. Ther. 1995, 273:1216-1223.
43. McCoy K.L., Matveyeva M., Carlisle S.J., Cabral G.A. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 1999, 289:1620-1625.
44. Molina-Holgado E., Vela J.M., Arevalo-Martin A., Almazan G., Molina-Holgado F., Borrell J., Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 2002, 22:9742-9753.
45. Montecucco F., Burger F., Mach F., Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1145-1155.
46. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
47. Ni X., Geller E.B., Eppihimer M.J., Eisenstein T.K., Adler M.W., Tuma R.F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler. 2004, 10:158-164.
48. Nilsson O., Fowler C.J., Jacobsson S.O. The cannabinoid agonist WIN 55, 212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells. Eur. J. Pharmacol. 2006, 547:165-173.
49. Palazuelos J., Davoust N., Julien B., Hatterer E., Aguado T., Mechoulam R., Benito C., Romero J., Silva A., Guzman M., Nataf S., Galve-Roperh I. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 2008, 283:13320-13329.
50. Parolaro D., Massi P., Rubino T., Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:319-332.
51. Patel V., Borysenko M., Kumar M.S., Millard W.J. Effects of acute and subchronic delta 9-tetrahydrocannabinol administration on the plasma catecholamine, beta-endorphin, and corticosterone levels and splenic natural killer cell activity in rats. Proc. Soc. Exp. Biol. Med. 1985, 180:400-404.
52. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 2005, 76:1307-1324.
53. Piccio L., Rossi B., Colantonio L., Grenningloh R., Gho A., Ottoboni L., Homeister J.W., Scarpini E., Martinello M., Laudanna C., D'Ambrosio D., Lowe J.B., Constantin G. Efficient recruitment of lymphocytes in inflamed brain venules requires expression of cutaneous lymphocyte antigen and fucosyltransferase-VII. J. Immunol. 2005, 174:5805-5813.
54. Piccio L., Rossi B., Scarpini E., Laudanna C., Giagulli C., Issekutz A.C., Vestweber D., Butcher E.C., Constantin G. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J. Immunol. 2002, 168:1940-1949.
55. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., Ledent C., Petzold A., Thompson A.J., Giovannoni G., Cuzner M.L., Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126:2191-2202.
56. Reyes-Irisarri E., Sanchez A.J., Garcia-Merino J.A., Mengod G. Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 2007, 66:923-931.
57. Rhee M.H., Kim S.K. SR144528 as inverse agonist of CB2 cannabinoid receptor. J. Vet. Sci. 2002, 3:179-184.
58. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010, 215:598-605.
59. Robbie-Ryan M., Brown M. The role of mast cells in allergy and autoimmunity. Curr. Opin. Immunol. 2002, 14:728-733.
60. Rossi S., Bernardi G., Centonze D. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp. Neurol. 2010, 224:92-102.
61. Samson M.T., Small-Howard A., Shimoda L.M., Koblan-Huberson M., Stokes A.J., Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J. Immunol. 2003, 170:4953-4962.
62. Shenoy P., Agarwal V. Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun. Rev. 2010, 9:511-515.
63. Shire D., Calandra B., Bouaboula M., Barth F., Rinaldi-Carmona M., Casellas P., Ferrara P. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci. 1999, 65:627-635.
64. Suzumura A., Nakamuro T., Tamaru T., Takayanagi T. Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors. Mult. Scler. 2000, 6:56-58.
65. Walter L., Stella N. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 2004, 141:775-785.
66. Wenger T., Fernandez-Ruiz J.J., Ramos J.A. Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland. J. Neuroendocrinol. 1999, 11:873-878.
67. Yuan M., Kiertscher S.M., Cheng Q., Zoumalan R., Tashkin D.P., Roth M.D. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 2002, 133:124-131.